Skip to main content
Fig. 6 | Fluids and Barriers of the CNS

Fig. 6

From: CNS endothelial derived extracellular vesicles are biomarkers of active disease in multiple sclerosis

Fig. 6

CNS-EEV populations are unique and are increased in RRMS patients with active disease. A Gating strategy for analysis of CD3/CD41- EV for expression of multiple endothelial markers. B Representative density plots of CD3/CD41- EV positive for CD31 versus CD105 (left), CD31 versus CD144 (center), or CD105 versus CD144 (right) when stained with anti-CD antibodies or appropriate isotype controls (IgG CT). C Percent of CD3/CD41- EV positive for indicated marker combinations. Results are expressed as a mean ± the STEDV of seven healthy controls (HC) or seven RRMS donors. Note that less than 1% of EV are positive for multiple markers, highlighted in red. D Total number of CNS-EEV per μL plasma was calculated by adding the levels of CSN-EEV31, CNS-EEV105, CNS-EEV144 for each separate donor. Calculated total CNS-EEV per μL of plasma for different patient groups including HC, active RRMS patients not receiving DMT (Active), stable RRMS patients not receiving DMT (Stable), or stable RRMS patients receiving natalizumab (NTZ) or ocrelizumab (OCZ). Results are displayed as box and whisker plots with each dot representing an individual donor. *** p ≤ 0.001 determined by one-way ANOVA with post-hoc Tukey HSD Test

Back to article page